Platelet-to-lymphocyte ratio in the setting of liver transplantation for hepatocellular cancer: A systematic review and meta-analysis

Table 2 Demographic and clinical aspects of the selected studies

Ref.	n	Age	Male gender (%)	waiting time (mo)	MELD	Underlying disease	Major lesion diam (cm)	Number lesions	MC-OUT (%)	AFP ≥ 200 ng/mL (%)	LRT (%)	Cut-off	AUROC	> cut-off (%)	Recurr (%)	5-yr TFS
Xia et al[24]	343	49 ± 10	308 (90)	NA	13 ± 6	HBV = 320	> 5:110	> 3:91	199 (58)	165 (48)	222 (65)	150	0.63	33 (10)	NA	< 150: 52
						Other = 23										≥ 150:25
Lai et al[25]	146	58 (54-63)	116 (80)	8 (3-10)	11 (8-11)	HCV = 63	2.5 (1.7-3.5)	1 (1-2)	32 (22)	8 (6)	136 (93)	150	0.66	28 (19)	14 (10)	< 150:92
						HBV = 26										≥ 150:81
						Other = 57
Parisi et al[26]	150	54 ± 7	125 (83)	2 (0-12)	NA	HCV = 60	2.7	1	0 (-)	13 (9)	71 (47)	150	NA	17 (11)	19 (13)	NA
						HBV = 34
						Other = 56
Nicolini et al[27]	70	57 (51-62)	62 (89)	NA	11 (7-15)	HCV = 41	1.3 (0.0-2.1)	1 (0-2)	12 (17)	6 (9)1	70 (100)	150	NA	5 (7)	8 (11)	< 150:89
						HBV = 15										≥ 150:50
						Other = 14
Harimoto et al[28]	190	≥ 59:97	107 (56)	NA	≥ 15:60	HCV = 134	> 5:8	> 3:41	66 (35)	30 (16)2	NA	70.4	0.70	97 (51)	28 (15)	< 70.4:95
						Other = 56										≥ 70.4:76

¹AFP ≥ 400 ng/mL;

²AFP ≥ 300 ng/mL. MELD: Model for end-stage liver disease; MC: Milan Criteria; AFP: Alpha-fetoprotein; LRT: Locoregional treatment; AUROC: Area under the receiver operator curve; TFS: Tumor-free survival; HCV: Hepatitis C virus; HBV: Hepatitis B virus; NA: Not available.